Karin sells VRTX 88.91: Vertex Pharma (VRTX) Receives EC Approval of KALYDECO in Certain Patients with CF
Vertex Pharma (Nasdaq: VRTX) announced that the European Commission has approved KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance .. ...
27 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home